References
- Braman SS. The global burden of asthma. Chest 130(1 Suppl.), 4S–12S (2006).
- Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59(5), 469–478 (2004).
- Szefler SJ, Martin RJ, King TS et al.; Asthma Clinical Research Network of the National Heart Lung, and Blood Institute. Significant variability in response to inhaled corticosteroids for persistent asthma. J. Allergy Clin. Immunol. 109(3), 410–418 (2002).
- Szpirer J, Szpirer C, Riviere M et al. The Sp1 transcription factor gene (SP1) and the 1,25-dihydroxyvitamin D3 receptor gene (VDR) are colocalized on human chromosome arm 12q and rat chromosome 7. Genomics 11(1), 168–173 (1991).
- Lötvall J, Akdis CA, Bacharier LB et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J. Allergy Clin. Immunol. 127(2), 355–360 (2011).
- Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am. Rev. Respir. Dis. 136(1), 225–244 (1987).
- Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am. J. Respir. Crit. Care Med. 162(6), 2341–2351 (2000).
- Lougheed MD, Lemière C, Dell SD et al.; Canadian Thoracic Society Asthma Committee. Canadian Thoracic Society Asthma Management Continuum – 2010 Consensus Summary for children six years of age and over, and adults. Can. Respir. J. 17(1), 15–24 (2010).
- Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 372(9643), 1107–1119 (2008).
- Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin. Exp. Allergy 42(5), 650–658 (2012).
- Poon AH, Eidelman DH, Martin JG, Laprise C, Hamid Q. Pathogenesis of severe asthma. Clin. Exp. Allergy 42(5), 625–637 (2012).
- Piquette-Miller M, Grant DM. The art and science of personalized medicine. Clin. Pharmacol. Ther. 81(3), 311–315 (2007).
- Waldman SA, Terzic A. Widening the path to personalized medicine. Clin. Transl. Sci. 4(5), 392–394 (2011).
- Poon AH, Hamid Q. Personalized medicine for asthma: are we there yet? Ann. Thorac. Med. 7(2), 55–56 (2012).
- Kuhl K, Hanania NA. Targeting IgE in asthma. Curr. Opin. Pulm. Med. 18(1), 1–5 (2012).
- Corren J, Lemanske RF, Hanania NA et al. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med. 365(12), 1088–1098 (2011).
- Haldar P, Brightling CE, Hargadon B et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360(10), 973–984 (2009).
- Nair P, Pizzichini MM, Kjarsgaard M et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med. 360(10), 985–993 (2009).
- Cox G, Thomson NC, Rubin AS et al.; AIR Trial Study Group. Asthma control during the year after bronchial thermoplasty. N. Engl. J. Med. 356(13), 1327–1337 (2007).
- Pavord ID, Cox G, Thomson NC et al.; RISA Trial Study Group. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am. J. Respir. Crit. Care Med. 176(12), 1185–1191 (2007).
- Castro M, Rubin AS, Laviolette M et al.; AIR2 Trial Study Group. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am. J. Respir. Crit. Care Med. 181(2), 116–124 (2010).